43,894 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Acquired by Dynamic Technology Lab Private Ltd

Dynamic Technology Lab Private Ltd bought a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 43,894 shares of the company’s stock, valued at approximately $1,252,000. Dynamic Technology Lab Private Ltd owned 0.16% of Castle Biosciences as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Marshall Wace LLP boosted its stake in shares of Castle Biosciences by 116.5% in the second quarter. Marshall Wace LLP now owns 212,036 shares of the company’s stock valued at $4,616,000 after purchasing an additional 114,104 shares during the period. Harbor Capital Advisors Inc. boosted its position in Castle Biosciences by 249.3% in the 2nd quarter. Harbor Capital Advisors Inc. now owns 138,707 shares of the company’s stock valued at $3,020,000 after buying an additional 99,001 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Castle Biosciences by 147.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,458 shares of the company’s stock worth $4,719,000 after acquiring an additional 98,571 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Castle Biosciences by 47.3% during the second quarter. Renaissance Technologies LLC now owns 301,500 shares of the company’s stock worth $6,564,000 after acquiring an additional 96,800 shares during the period. Finally, Lisanti Capital Growth LLC acquired a new stake in shares of Castle Biosciences in the second quarter valued at $2,102,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CSTL has been the subject of several analyst reports. KeyCorp boosted their target price on Castle Biosciences from $28.00 to $36.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Canaccord Genuity Group boosted their price objective on Castle Biosciences from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, October 29th. Scotiabank raised their target price on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a report on Wednesday, November 6th. Robert W. Baird boosted their price target on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Finally, BTIG Research raised their price objective on shares of Castle Biosciences from $35.00 to $40.00 and gave the company a “buy” rating in a report on Monday, October 14th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $37.88.

Castle Biosciences Trading Up 3.6 %

Shares of Castle Biosciences stock opened at $30.57 on Wednesday. The company has a current ratio of 7.78, a quick ratio of 7.64 and a debt-to-equity ratio of 0.02. The company has a fifty day simple moving average of $30.94 and a 200-day simple moving average of $26.58. The stock has a market cap of $856.27 million, a price-to-earnings ratio of 152.86 and a beta of 0.99. Castle Biosciences, Inc. has a 12-month low of $16.97 and a 12-month high of $35.84.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings data on Monday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.14. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. The company had revenue of $85.78 million during the quarter, compared to the consensus estimate of $78.55 million. During the same quarter in the prior year, the firm posted ($0.26) earnings per share. On average, equities analysts forecast that Castle Biosciences, Inc. will post -0.08 EPS for the current fiscal year.

Insider Buying and Selling

In other Castle Biosciences news, CFO Frank Stokes sold 6,923 shares of the firm’s stock in a transaction on Friday, November 15th. The shares were sold at an average price of $29.93, for a total transaction of $207,205.39. Following the transaction, the chief financial officer now directly owns 30,823 shares of the company’s stock, valued at approximately $922,532.39. This trade represents a 18.34 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Derek J. Maetzold sold 1,972 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $34.15, for a total transaction of $67,343.80. Following the completion of the sale, the insider now directly owns 87,720 shares of the company’s stock, valued at $2,995,638. The trade was a 2.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,213 shares of company stock worth $752,673 in the last quarter. 7.20% of the stock is owned by insiders.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.